Georgia Power has launched the Robins Battery Facility, a 128 MW battery energy storage system near Warner Robins, Georgia. This facility stores solar energy for up to four hours, enhancing grid reliability and flexibility during peak demand. It complements the nearby Robins Solar Facility, supporting Georgia's growing energy needs and economic development. The project is part of Georgia Power's broader plan to expand battery storage capacity across the state, with several other facilities underway or approved to strengthen the energy grid with renewable sources.
Georgia Power's Robins Battery Storage system is the subject, with Pluang's Utilities sector market data as context. For readers following Utilities, here is Pluang's market snapshot as of Sep 15, 2026 22:51 WIB: out of 23 priced US Utilities stocks, 4 rose and 19 fell. Notable movers include SRE at USD 81.96 down 1.24%, TDW at USD 89.62 up 1.17%, and AEP at USD 120.98 down 1.02%.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
